Differences in genomic alterations between patients with lung adenocarcinoma and with lung squamous cell carcinoma

In this study, we carried out targeted next-generation sequencing (NGS) of tumor tissue DNA from 91 NSCLC patients and plasma-derived ctDNA of 89 NSCLC patients by a hybridization capture-based panel including 82 tumor-related genes. The differences in somatic mutations, somatic interactions, key signaling pathways, functional biological information, and clinical actionability for the therapy of targeted agents were explored between 148 patients with LUAD and 32 patients with LUSC.